Your browser doesn't support javascript.
loading
Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.
Park, Jeenah; Thomas, Scott; Zhong, Allison Y; Wolfe, Alan R; Krings, Gregor; Terranova-Barberio, Manuela; Pawlowska, Nela; Benet, Leslie Z; Munster, Pamela N.
Afiliación
  • Park J; Division of Hematology and Oncology, University of California, San Francisco, USA.
  • Thomas S; Division of Hematology and Oncology, University of California, San Francisco, USA.
  • Zhong AY; Department of Molecular and Cell Biology, University of California, Berkeley, USA.
  • Wolfe AR; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, USA.
  • Krings G; Department of Pathology, University of California, San Francisco, USA.
  • Terranova-Barberio M; Division of Hematology and Oncology, University of California, San Francisco, USA.
  • Pawlowska N; Division of Hematology and Oncology, University of California, San Francisco, USA.
  • Benet LZ; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, USA.
  • Munster PN; Division of Hematology and Oncology, University of California, San Francisco, USA. pamela.munster@ucsf.edu.
Sci Rep ; 8(1): 92, 2018 01 08.
Article en En | MEDLINE | ID: mdl-29311658
Broad use of germline testing has identified an increasing number of women at risk for breast cancer with a need for effective chemoprevention. We report a novel method to selectively deliver various anti-estrogens at high drug levels to the breast tissue by implanting a device comprised of silastic tubing. Optimized tubing properties allow elution of otherwise poorly bioavailable anti-estrogens, such as fulvestrant, into mammary tissue in vitro and in vivo with levels sufficient to inhibit estrogen receptor activation and tumor cell proliferation. Implantable silastic tubing delivers fulvestrant selectively to mouse mammary fat tissue for one year with anti-tumor effects similar to those achieved with systemic fulvestrant exposure. Furthermore, local delivery of fulvestrant significantly decreases cell proliferation, as assessed by Ki67 expression, most effectively in tumor sections adjacent to tubing. This approach may thereby introduce a potential paradigm shift and offer a promising alternative to systemic therapy for prevention and early interception of breast cancer.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Quimioprevención / Antineoplásicos Hormonales Límite: Animals / Female / Humans Idioma: En Revista: Sci Rep Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Quimioprevención / Antineoplásicos Hormonales Límite: Animals / Female / Humans Idioma: En Revista: Sci Rep Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos